October 2024: Top biotech deals of the month
This issue of our newsletter is supported by Inpart.
Post the September hiatus in the industry, partnering activity in various therapeutic fields was back up again in October, with major collaborations in oncology, metabolic diseases, small molecules, and gene therapies. And many biotechs once again joined the billion-dollar club in October with their partnership deals.
For example, neuroscience company Aliada Therapeutics was acquired by AbbVie and can cash $1.4 billion as part of the agreement. Modifi Biosciences was also involved in an acquisition deal – this time it was Merck doing the acquiring in a buyout worth $1.3 billion.?
Plus, there were plenty of other impressive deals that took place in October.
To find out more, read the full article: “Top biotech deals of October 2024 ”
A MESSAGE FROM OUR SPONSOR INPART
Nanotechnology: R&D trends and breakthrough innovations report
Nanotechnology innovation is crucial across medicine, healthcare, and medical tech in developing more efficient, sustainable, and precise solutions.?
Check out our report exploring R&D trends and breakthrough innovations leveraging the nanoscale to drive change across sectors, including an industry sentiment analysis and an R&D healthcheck from the NIA.
Want to advertise with us? Become our next sponsor.
?? More noteworthy articles from this week:
T cell engagers are engineered to redirect the immune system’s T cells to recognize and kill cancer cells, as they are designed to bind to a target antigen expressed on a cancer cell and trigger a molecule on T cells. Some big names within the biopharma industry have taken to developing or investing in T cell engagers, and several biotech companies have also recently launched specifically to develop these types of medicines. Here, we take a look at five T cell engager companies.
Scientific progress is exponential, and we are seeing innovations almost every day – some of which are innovations that we would only dream about in sci-fi movies 30 years ago. In a special article for Halloween, we explore some biotech catastrophic scenarios involving AI, a real-life Jurassic Park scenario, and animal hybridization – scenarios that might just keep you awake at night.
With traditional research methods alone proving insufficient, AI has emerged in Alzheimer’s research, tackling hurdles in drug discovery and diagnostics. AI’s ability to analyze massive datasets and model biological processes opens opportunities for early detection, understanding disease mechanisms, and even predicting drug efficacy. The field already benefited from significant improvements, but can AI bring even more to Alzheimer’s research?
In October 2023, Sanofi announced plans to separate its consumer health unit – which contributed flagship products like Doliprane and Allegra – in 2024. However, as CEO Paul Hudson implements his “play to win” strategy, these products, while strong, do not align with Sanofi’s evolving vision to lead in high-impact, high-growth areas like oncology, immunology, and vaccines. In this article, we explore Sanofi’s strategic shift.?
As the market for advanced cell models is currently booming, 3D organoids stand out amongst other advanced cell models for their nuanced simulation of human organs. In fact, they are already transforming research in oncology, neuroscience, and immunology and have great potential for further advancing drug development. Our comprehensive report, sponsored by Sartorius, examines the evolution, advantages, current applications, and future potential of 3D organoids.
U.K. company Sitryx Therapeutics is a leader in the field of immunometabolism, an area of immunology that looks to rebalance the immune system to achieve sustained disease remission in autoimmune and inflammatory diseases. The company has a broad pipeline of small molecules against novel targets in major autoimmune indications with high unmet needs. To talk about immunometabolism, our guest on the podcast this week is CEO of Sitryx Therapeutics, Iain Kilty.
Adeno-associated viruses (AAVs) are promising delivery tools for gene therapy and are used in many clinical studies. However, less than ten AAV-based therapies have been approved to date. To mitigate the risk of serious side effects and even death, a comprehensive quality control and characterization process is crucial. This process includes identifying features that may influence efficacy and safety but are not yet fully understood.
??Enjoying these articles??Never miss a single publication of Labiotech by becoming a part of our community! Click here to join our mailing list.